Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Abstract Background Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and management of this fatal complication. Methods We reviewed our instituti...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Houssein Safa, Daniel H Johnson, Van Anh Trinh, Theresa E Rodgers, Heather Lin, Maria E Suarez-Almazor, Faisal Fa’ak, Chantal Saberian, Cassian Yee, Michael A Davies, Sudhakar Tummala, Karin Woodman, Noha Abdel-Wahab, Adi Diab
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2019-11-01
coleção:	Journal for ImmunoTherapy of Cancer
Assuntos:	Myasthenia gravis Immune checkpoint inhibitors Nivolumab Pembrolizumab Ipilimumab Immunotherapy
Acesso em linha:	http://link.springer.com/article/10.1186/s40425-019-0774-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!